Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The approval was received at a special meeting of shareholders.
The transaction involves the acquisition of all common shares of Repare Therapeutics Inc.
Approval of Acquisition
Shareholders voted overwhelmingly in favor of the acquisition by XenoTherapeutics, Inc.
Compensation Approval
Shareholders also approved the compensation for the named executive officers related to the arrangement.
Liquidation Approval
In the event of termination, shareholders approved the voluntary liquidation and dissolution of Repare Therapeutics Inc.
- The transaction is subject to the approval of the Superior Court of Québec and other customary closing conditions.
- The expected completion date of the acquisition is around January 28, 2026.
- Repare Therapeutics Inc. will align its future strategies with XenoTherapeutics, Inc.'s goals.
The approval of the acquisition marks a significant step for Repare Therapeutics Inc. as it moves towards a new phase of collaboration with XenoTherapeutics, Inc.